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Gastrointestinal dysfunction is a common side-effect of chemotherapy leading to dose
reductions and treatment delays. These side-effects may persist up to 10 years
post-treatment. A topoisomerase I inhibitor, irinotecan (IRI), commonly used for the
treatment of colorectal cancer, is associated with severe acute and delayed-onset
diarrhea. The long-term effects of IRI may be due to damage to enteric neurons
innervating the gastrointestinal tract and controlling its functions. Balb/c mice received
intraperitoneal injections of IRI (30 mg/kg−1) 3 times a week for 14 days, sham-treated
mice received sterile water (vehicle) injections. In vivo analysis of gastrointestinal transit
via serial x-ray imaging, facal water content, assessment of gross morphological damage
and immunohistochemical analysis of myenteric neurons were performed at 3, 7 and 14
days following the first injection and at 7 days post-treatment. Ex vivo colonic motility
was analyzed at 14 days following the first injection and 7 days post-treatment. Mucosal
damage and inflammation were found following both short and long-term treatment with
IRI. IRI-induced neuronal loss and increases in the number and proportion of ChAT-IR
neurons and the density of VAChT-IR fibers were associated with changes in colonic
motility, gastrointestinal transit and fecal water content. These changes persisted in
post-treatment mice. Taken together this work has demonstrated for the first time that
IRI-induced inflammation, neuronal loss and altered cholinergic expression is associated
with the development of IRI-induced long-term gastrointestinal dysfunction and diarrhea.
Keywords: irinotecan, enteric neuropathy, cholinergic neurons, gastrointestinal dysfunction, chemotherapy
McQuade et al. Irinotecan-Induced Gastrointestinal Dysfunction
INTRODUCTION
A combination of irinotecan (IRI) with 5-fluorouracil (5-FU) and
leucovorin (LV) (FOLFIRI) is a common and effective therapy
administered to CRC patients (Conti et al., 1996; Saltz et al.,
2000). IRI is a semi-synthetic analog of the naturally occurring
quinoline alkaloid, camptothecin, and exerts its cytotoxicity via
inhibition of topoisomerase I (Top I) triggering S-phase specific
cell death (Xu and Villalona-Calero, 2002). Top I is essential for
transcription and acts to cut, relax, and reanneal DNA strands.
IRI’s active metabolite SN-38 binds to Top I and its DNA
complex, resulting in the formation of a stable ternary structure
that prevents DNA re-ligation and promotes DNA damage and
apoptosis (Xu and Villalona-Calero, 2002).
Clinical trials in patients with metastatic CRC have
demonstrated a significant survival advantage for FOLFIRI
compared with 5-FU/LV alone (Douillard et al., 2000; Saltz et al.,
2000), but major dose-limiting toxicities such as neutropenia
and chronic diarrhea diminish the clinical efficacy of FOLFIRI
treatment (Armand, 1996; Rothenberg et al., 1996; Weekes
et al., 2009). Although neutropenia is manageable, IRI-induced
diarrhea is typically severe, resulting in hospitalisations, dose-
reductions and delays, and termination of treatment in many
cases (Swami et al., 2013). Though the prevalence and severity of
IRI-induced diarrhea vary greatly depending on regime specifics
such as dosage and adjuvant therapies, rates as high as 80% have
been reported (Rothenberg et al., 1996).
IRI induces both acute and delayed-onset diarrhea. Acute
diarrhea experienced within the first 24 h following IRI
administration, occurs in 60–80% of patients (Gibson and
Stringer, 2009). Delayed-onset diarrhea arises at least 24 h after
IRI administration and occurs in approximately 80% of patients
(Saliba et al., 1998). Chemotherapy-induced diarrhea (CID) been
linked to early death rates of up to 5% in patients receiving IRI in
combination with 5-FU/LV (Rothenberg et al., 2001).
A number of different mechanisms for the gastrointestinal
side-effects of IRI treatment have been proposed including
luminal accumulation and reactivation of SN-38, sustained
disruption to intestinal microflora and continual mucosal
damage (Javle et al., 2007; Gibson and Stringer, 2009; Stringer
et al., 2009a; McQuade et al., 2014). Although the acute
diarrhea is thought to be primarily secretory with attenuation of
symptoms by administration of atropine suggesting involvement
of cholinergic secretomotor neurons, the underlying mechanism
of delayed onset IRI-induced diarrhea is unclear (Gibson et al.,
2003; Gibson and Stringer, 2009). We hypothesized that the
persistent recurring and long-term gastrointestinal symptoms
associated with IRI treatment may result from damage to the
intrinsic nervous system of the gastrointestinal tract, the enteric
Abbreviations: 5-FU, 5-fluorouracil; ChAT, choline acetyltransferase; CID,
chemotherapy-induced diarrhea; CRC, colorectal cancer; CMMC, colonic
migrating motor complex; ENS, enteric nervous system; FC, fragmented
contraction; FOLFIRI, 5-fluorouracil, leucovorin and irinotecan; IR,
immunoreactive; IRI, irinotecan; LV, leucovorin; PGP 9.5, Protein Gene Product
9.5; SC, short contraction; Top I, topoisomerase I; VAChT, vesicular acetylcholine
transporter.
nervous system (ENS). We tested this and found that IRI
treatment produced gastrointestinal dysfunction that correlated
with loss of enteric neurons, but a substantial increase in the
number of cholinergicmyenteric neurons, consistent with enteric
neuropathy being a major cause of IRI induced diarrhea.
METHODS
Ethical Approval
All procedures were approved by the Victoria University
Animal Experimentation Ethics Committee and performed in
accordance with the guidelines of the National Health and
Medical Research Council (NHMRC) Australian Code of Practice
for the Care and Use of Animals for Scientific Purposes.
Animals
Male Balb/c mice aged 6–8 weeks (18–25 g) supplied from the
Animal Resources Centre (Perth, Australia) were used for the
experiments. Mice had free access to food and water and were
kept under a 12 h light/dark cycle in a well-ventilated room
at an approximate temperature of 22◦C. Mice acclimatized for
a minimum of 5 days prior to the commencement of in vivo
intraperitoneal injections. Mice were euthanized via cervical
dislocation. A total of 56 mice were used for this study.
In vivo Irinotecan Injections
Mice received intraperitoneal injections of IRI (30 mg/kg−1)
(Sigma-Aldrich, Australia)via a 26 gauge needle, once a day, 3
times a week over a 14 day period to a total of 6 injections.
Injections began at Day 0 and continued on Day 2, Day 4,
Day 7, and Day 9, the final injection was given on Day 11.
IRI was dissolved in sterile water to make 10−1 M L−1 stock
solutions refrigerated at −20◦C. The stock was then defrosted
and diluted with sterile water to make 10−2 M L−1 solutions
for intraperitoneal injections via a 26 gauge needle. The dose of
IRI was calculated to reach a cumulative dose equivalent to a
standard human dose in combination therapy, 180 mg/m2 per
body surface area (Reagan-Shaw et al., 2008; Köhne et al., 2012).
Sham-treated mice received sterile water via intraperitoneal
injections 3 times a week. The injected volumes were calculated to
the body weight; the maximum volume of injected IRI or vehicle
did not exceed 200 µL per injection. Mice were euthanized via
cervical dislocation at Day 3 (after receiving 2 treatments), Day
7 (after receiving 3 treatments), and Day 14 (after receiving 6
treatments). Post-treatment group mice were euthanized 7 days
after the final injection (6 treatments). Colons from all groups
were collected for in vitro experiments.
A separate cohort of mice was used for food consumption
experiments. IRI was dissolved in 0.1% dimethyl sulfoxide
(DMSO) (Sigma-Aldrich, Australia) in sterile water to make 10−2
M L−1 solutions for intraperitoneal injections. Sham-treated
mice received 0.1% DMSO in sterile water.
Gastrointestinal Transit
Gastrointestinal transit was studied by X-ray prior to first
treatment (day 0) and at 3, 7, and 14 days and 7 days post-
treatment of IRI treatment (n = 5 mice/group) as described
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previously (McQuade R. et al., 2016; McQuade R. M. et al.,
2016). Briefly, the contrast agent, 0.4 mL of suspended barium
sulfate (X-OPAQUE-HD, 2.5 g/mL), was administered via oral
gavage. Prior to performing X-ray imaging, animals were
trained/conditioned for oral gavage using either 0.9% w/v saline
or sterile water (volume 0.1–0.4 ml); this was repeated at least 3
times for each animal with at least 24 h between each training
session. Radiographs of the gastrointestinal tract were taken
using a HiRay Plus Porta610HF X-ray apparatus (JOC Corp,
Kanagawa, Japan; 50 kV, 0.3 mAs, exposure time 60 ms). Mice
were immobilized in the prone position by placing them inside
a transparent plastic restraint tube with partly open front side
for breathing, this comfortably restrains animal movement for
a maximum of 1–2 min which is essential for successful X-
ray imaging. The training/conditioning with restraint was done
by placing the restrainer into the mouse cages at least 24
h prior to the X-ray procedure. X-rays were captured using
Fujifilm cassettes (24× 30 cm) immediately after administration
of barium sulfate (T0), every 5 min for the first hour, every
10 min for the second hour, then every 20 min through to
360 min (T360). Animals were closely monitored during and
after all procedures. Images were developed via a Fujifilm FCR
Capsula XLII and analyzed using eFilm 4.0.2 software. Speed of
gastrointestinal transit was calculated as time in min taken to
reach each region of the gastrointestinal tract (stomach, small
intestines, caecum, and colon). Organ emptying was calculated
as the time taken for complete barium emptying from specific
gastrointestinal regions (stomach, small intestines) (Cabezos
et al., 2008, 2010; Girón et al., 2015).
Faecal Water Content and Colonic Faecal
Content Analysis
Fresh fecal pellets were collected from both sham and IRI-
treated mice (n = 10 mice/group). Individual mice were placed
in holding cages for a period of 15–30 min, the first 5 fresh pellets
expelled were collected and weighed immediately to calculate
average fresh wet weight. Pellets were then dehydrated for 72 h at
room temperature prior tomeasurement of the dry weight.Water
content was calculated as the difference between the wet weight
and dry weight. Pellet length was measured in arbitrary units
and converted to µm in all X-ray images displaying discernible
pellets in the distal colon using an Image J measurement tool. X-
ray images were converted to TIFF format and set to 800 × 800
pixels.
Colonic Motility Experiments
The entire colon was removed from day 14 and post-
treatment sham and IRI-treated mice (n = 5 mice/group)
and set up in organ-bath chambers to record motor patterns
ex vivo (Wafai et al., 2013). Briefly, the colon was placed
into warmed (35◦C), oxygenated physiological saline until the
fecal pellets were expelled. The empty colon was cannulated
at both ends and arranged horizontally in an organ-bath
chamber. The proximal end of the colon was connected to a
reservoir containing oxygenated physiological saline to maintain
intraluminal pressure. The distal end was attached to an outflow
tube that provided a maximum of 2 cm H2O back-pressure.
Organ baths were continuously superfused with oxygenated
physiological saline and preparations were left to equilibrate for
30 min. Contractile activity of each segment was recorded with
a Logitech Quickcam Pro camera positioned 7–8 cm above the
preparation. Videos (2 × 20 min) of each test condition were
captured and saved in avi format using VirtualDub software
(version 1.9.11).
Recordings were used to construct spatiotemporal maps
using in-house edge detection software (Gwynne et al., 2004).
Spatiotemporal maps plot the diameter of the colon at all points
during the recording allowing contractile motor patterns to be
analyzed with Matlab software (version 12). Colonic migrating
motor complexes (CMMCs) were defined as propagating
contractions directed from the proximal to the distal end
of the colon which traveled more than 50% of the colon
length (Spencer and Bywater, 2002; Roberts et al., 2007, 2008).
Contractions that propagated less than 50% of the colonic length
were considered to be short contractions (SCs). Incomplete
contractions occurring synchronously at different parts of the
colon rather than propagating over the length of the colon were
defined as fragmented contractions (FCs) (McQuade R. et al.,
2016).
Histology
The colon was harvested and placed in a 10% formalin solution
overnight and then transferred into 70% ethanol the following
day. Paraffin embedded colon sections were cut 5 µm thick
and deparaffinized, cleared, and rehydrated in graded ethanol
concentrations.). To examine the morphological changes to
the colon, standard Haematoxylin, and Eosin (H&E) staining
protocol was followed (McQuade R. et al., 2016). Ten randomly
selected sections per preparation were analyzed and scored on
the following parameters: changes in crypt architecture (0–5),
reduction in crypt length (0–5), mucosal ulceration (0–5), and
immune cell infiltration (0–5) (total score 20) (Rahman et al.,
2016). All images were analyzed blindly.
Immunohistochemistry in Cross Sections
Colon samples were cut open along the mesenteric border,
cleared of their contents, and pinned mucosa up without
stretching (n= 5mice/group). Tissues were fixed with Zamboni’s
fixative overnight at 4◦C. Preparations were cleared of fixative
by washing 3 × 10 min with DMSO (Sigma-Aldrich, Australia)
followed by 3 × 10min washes with PBS. After washing, tissues
were embedded in 100% OCT and frozen using liquid nitrogen
(LN2) and isopentane (2-methyl butane) and stored in −80
◦C
freezer. Tissues were cut at 20 µm section thickness using a
Leica CM1950 cryostat (Leica Biosystems, Germany), adhered to
slides and allowed to rest for 30min at room temperature before
processing.
Cross section preparations were incubated with 10% normal
donkey serum (Chemicon, USA) for 1 h at room temperature.
Tissues were then washed (2 × 5min) with PBS and incubated
with primary antibodies against CD45 (rat, 1:500, BioLegend,
Australia), overnight at 4◦C. Sections were then washed in
PBS (3 × 10min) before incubation with secondary antibodies
labeled with fluorophore donkey anti-rat Alexa 488 (1:200,
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Jackson Immunoresearch Laboratories, PA, USA) for 2 h at room
temperature. The sections were given 3 × 10min final washes
in PBS and then cover slipped using fluorescence mounting
medium (DAKO, Australia).
Immunohistochemistry in Wholemount
Preparations
Segments of the distal colon (2–3 cm) were placed in oxygenated
phosphate-buffered saline (PBS) (pH 7.2) containing nicardipine
(3 µM) (Sigma-Aldrich, Australia) for 20 min to inhibit smooth
muscle contractions (n = 5 mice/group). Samples were cut open
along the mesenteric border, cleared of their contents, maximally
stretched and pinned mucosa down. Tissues were fixed with
Zamboni’s fixative (2% formaldehyde, 0.2% picric acid) overnight
at 4◦C. Preparations were cleared of fixative by washing 3 ×
10 min with DMSO (Sigma-Aldrich, Australia) followed by 3 ×
10 min washes with PBS. Once washed, tissues were dissected
mucosa up to expose the myenteric plexus. Fixed tissues were
stored at 4◦C in PBS for a maximum of 5 days.
Wholemount preparations were incubated with 10% normal
donkey serum (Chemicon, USA) for 1 h at room temperature.
Tissues were then washed (2 × 5 min) with PBS and
incubated with primary antibodies against Protein Gene Product
9.5 (PGP9.5) (chicken, 1:500, Abcam, MA, USA), choline
acetyltransferase (ChAT) (goat, 1:500, Abcam, MA, USA) or
vesicular acetylcholine transporter (VAChT) (goat, 1:500, Abcam,
MA, USA) overnight at 4◦C. Tissues were then washed in PBS
(3 × 10 min) before incubation with species-specific secondary
antibodies labeled with different fluorophores: donkey anti-
chicken Alexa 594 (1:200, Jackson Immunoresearch Laboratories,
PA, USA) and donkey anti-goat Alexa 488 (1:200, Jackson
Immunoresearch Laboratories, PA, USA) for 2 h at room
temperature. Wholemount preparations were given 3 × 10 min
final washes in PBS and then mounted on glass slides using
fluorescent mounting medium (DAKO, Australia).
Imaging
Wholemount preparations and cross sections were viewed
under a Nikon Eclipse Ti laser scanning microscope. Eight
randomly chosen three dimensional (z-series) images from each
preparation were captured with a x20 objective and processed
using NIS Elements software (Nikon, Japan). Fluorophores were
visualized using excitation filters for Alexa 594 Red (excitation
wavelength 559 nm), Alexa 488 (excitation wavelength 473 nm),
and Alexa 405 (excitation wavelength 405 nm). Z-series images
were taken at step size of 1.75 µm (1,600 × 1,200 pixels). The
number of PGP9.5 and ChAT immunoreactive (IR) neurons
was quantified in the myenteric ganglia and CD45-IR cells in
cross sections were quantified within a 2 mm2 area of each
preparation. Quantitative analyses were conducted blindly. The
density of VAChT-IR fibers in cross sections of the colon was
measured from 8 images per preparation at x20 magnification
(total area 2 mm2). All images were captured at the same
distance from the tissue edges, at identical acquisition exposure-
time conditions, calibrated to standardized minimum baseline
fluorescence. Minimum baseline fluorescence was determined
from the sham-treated tissue, these acquisition settings were used
as the acquisition exposure-time for all samples. All images were
converted to binary, set to identical thresholds and changes in
fluorescence from baseline were measured as mean gray value
using Image J software (NIH, MD, USA). All images were
analyzed blindly. The density of immunoreactive fibers was then
expressed in arbitrary units.
Statistical Analysis
A one-way analysis of variance (ANOVA) with Tukey Kramer
post hoc test was performed to compare neurochemical and
gastrointestinal transit data between multiple groups. Student’s
unpaired two-tailed t-test was used to compare motility, pellet
length and fecal water content data. Analyses were performed
using Graph Pad Prism (Graph Pad Software Inc., CA, USA).
Data are presented as mean ± standard error of the mean
(SEM). Value differences were considered statistically significant
at P < 0.05.
RESULTS
Altered Gastrointestinal Transit Following
Irinotecan Administration
To determine the effects of IRI administration on gastrointestinal
transit, a series of radiographic images were used to track the
movement of barium sulfate through the gastrointestinal tract
before the first injection (day 0), after 2 injections (day 3), 3
injections (day 7), 6 injections (day 14 and 7 days post-treatment)
(Figure 1). Speed of barium movement was calculated by tracing
barium entry from one part of the gastrointestinal tract to the
next. Pellet formation time was calculated as the time taken
(in minutes) for the first pellet to form. After 3 days of IRI
administration, transit was significantly faster to the caecum and
colon and pellet formation was significantly quicker (Figure 2A,
Table 1). No differences in transit time to the caecum or colon
were found at days 7, 14 or post-treatment when compared to
day 0 (Figure 2A, Table 1).
Although tracing barium movement allowed for the analysis
of real time transit speed (the time for barium to reach
various parts of the gastrointestinal tract), gastrointestinal organ
filling and emptying does not happen simultaneously, therefore
we further analyzed the time taken for complete barium
emptying from specific gastrointestinal regions (indicative of the
gastrointestinal propulsive activity). Significant delays in gastric
emptying were found at all time points following IRI treatment
and post-treatment (Figure 2B, Table 1). No differences in
intestinal emptying were found following 3 or 7 days of IRI
administration, but intestinal emptying was significantly delayed
following 14 days of IRI treatment, as well as post-treatment,
compared to day 0 (Figure 2C, Table 1).
Colonic Fecal Content
To define the clinical symptoms resulting from the altered
patterns of colonic motor activity, pellet length in X-ray images
and fecal water content in freshly collected fecal pellets were
analyzed. Pellet length significantly increased after 7 and 14 days
of IRI treatment (P < 0.01 for both), as well as post-treatment
(P < 0.05), but no significant differences in pellet length were
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FIGURE 1 | In vivo recording of gastrointestinal transit following repeated IRI administration. Representative X-ray images obtained from mice 0 to 210 min after
intragastric barium sulfate (0.4mL, 2.5mg/mL) administration. X-ray imaging was performed at day 0 (prior to 1st injection) and following 3, 7, and 14 days of IRI
administration and 7 days post-treatment, n = 5 mice/group. Stomach (*), small intestines (#), caecum (1), pellet formation (†).
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FIGURE 2 | Quantitative analysis of X-ray images. Gastrointestinal transit time, gastric and intestinal emptying following repeated in vivo IRI administration. (A) Time
(min) taken for barium sulfate to reach the stomach, small intestines, caecum and colon before (day 0) and at 3, 7, and 14 days and 7 days post-treatment following
IRI administration. (B) Time (min) taken for complete emptying of barium from the stomach. (C) Time (min) taken for complete emptying of barium from the small
intestines. Data presented as mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared to day 0. n = 5 mice/group.
TABLE 1 | Speed of gastrointestinal transit and emptying following repeated in vivo irinotecan administration.
Parameters measured Day 0 Day 3 Day 7 Day 14 Post-treatment
Speed of transit (time to reach each region, min) Small Intestines 5 ± 0 5 ± 0 5 ± 0 5 ± 0 5 ± 0
Caecum 70 ± 3 45 ± 4*** 64 ± 5 70 ± 6 63 ± 3
Colon 90 ± 3 55 ± 4**** 92 ± 6 88 ± 3 83 ± 3
Time for complete barium emptying (min) Gastric emptying 17 ± 1 36 ± 3** 37 ± 2* 40 ± 3*** 53 ± 7****
Intestinal emptying 88 ± 2 80 ± 4 100 ± 7 104 ± 5**†† 126 ± 7**††††
Pellet Formation 90 ± 3 55 ± 4**** 92 ± 6†††† 88 ± 3†††† 83 ± 3††
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 significantly different to Day 0. ††P < 0.01, ††††P < 0.0001 significantly different to Day 3, n = 5 per group/time point.
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FIGURE 3 | Pellet length following repeated in vivo IRI administration. Representative X-ray images of fecal pellets before (day 0) (A), at 3 (B), 7 (C), 14 (D) days and
7 days post IRI treatment (E). (F) Length (µm) of fecal pellets before (day 0), at 3, 7, 14 days and 7 days post IRI treatment. Data presented as mean ± S.E.M. *P <
0.05, **P < 0.01 compared to day 14 sham, n = 5 mice/group.
found following 3 days of IRI treatment when compared to day 0
(Figure 3).
Fecal water content was calculated as the difference between
wet and dry pellet weight. The average wet weight of fresh pellets
from IRI-treatedmice was significantly greater than that of pellets
from sham-treated mice at all time points (day 3 sham: 54 ± 3.4
mg, IRI: 67± 2.8 mg, P < 0.01: day 7 sham: 57± 4.5 mg, IRI: 74
± 2.0 mg, P< 0.01; day 14 sham: 51± 2.9 mg, IRI: 74± 2.9 mg, P
< 0.0001; (post-treatment sham: 52± 1.9 mg, IRI: 95± 3.9 mg, P
< 0.0001) (Figure 4A). After dehydration, the average dry weight
of pellets from IRI-treated mice at day 3 was significantly less
than those from sham-treated mice (sham: 26 ± 1.5 mg, IRI: 19
± 2.7 mg, P < 0.05) (n = 10 mice/group) (Figure 4B). However,
the average dry weight from IRI-treated mice was significantly
greater than for pellets from sham-treated mice at day 7 (sham:
25 ± 2.3 mg, IRI: 34 ± 0.9 mg, P < 0.01), day 14 (sham: 25 ±
1.4 mg, IRI: 39± 2.3 mg, P< 0.0001) and post-treatment (sham:
25 ± 1.3 mg, IRI: 41 ± 2.3 mg, P < 0.0001) (n = 10 mice/group)
(Figure 4B). The water content was significantly higher in pellets
collected from IRI-treatedmice than pellets collected from sham-
treated mice at day 3 (sham: 52 ± 1.7%, IRI: 72 ± 3.2%, P <
0.0001), day 14 (sham: 51 ± 1.8%, IRI: 57 ± 1.2%, P < 0.05) and
post-treatment (53 ± 1.3 v, IRI: 57 ± 1.6%, P < 0.05) (n = 10
mice/group) (Figure 4C). No difference in water content between
sham-treated (56 ± 2.7%) and IRI-treated mice (54 ± 1.5%) was
found at day 7.
Changes in Colonic Motility Following
Irinotecan Administration
To investigate the effects of IRI on colonic motility controlled
by intrinsic innervation, excised colons were studied in organ
bath experiments at day 14 of IRI treatment and post-treatment
(Figure 5A). The total number of contractions (including all
types of motor activity in the colon: CMMCs, short and
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FIGURE 4 | Fecal water content following repeated in vivo IRI administration.
(A) Wet weight of fecal pellets measured immediately upon pellet expulsion.
(B) Dry weight of fecal pellets measured after 72 h of dehydration at room
temperature. (C) Faecal water content calculated as the difference between
the wet weight and dry weight. *P < 0.05, **P < 0.01, ****P < 0.0001, n = 10
mice/group.
fragmented contractions) was increased in the colons from day
14 IRI-treated (P < 0.01) and post-treatment (P < 0.0001)
animals compared to sham-treated mice (Figure 5B, Table 2). To
determine if this was due to changes in a specific type of motor
activity, the frequency and proportion were analyzed for each
type of motor contractions.
A decrease in the frequency and proportion of CMMCs was
observed in the colons from day 14 IRI-treated compared to
sham-treated animals (P < 0.0001 for both) (Figures 5B,C,
Table 2). The decrease in frequency (P < 0.001) and
proportion (P < 0.0001) of CMMCs persisted in the colons
from post-treatment mice compared to sham-treated animals
(Figures 5B,C, Table 2).
Following 14 days treatment with IRI, the frequency of SCs
in the colon was greater compared to sham-treated colon (P <
0.05) (Figure 5B, Table 2), but no significant difference in the
proportion of SCs was found in day 14 IRI-treated compared
to sham-treated mice (Figure 5C). Similarly, the frequency of
SCs in the colon increased in post-treatment mice compared to
sham-treated mice (P < 0.01) (Figure 5B, Table 2), but without
a change in the proportion of SCs in post-treatment mice when
compared to sham-treated mice (Figure 5C).
Both the frequency and the proportion of FCs was
significantly higher in IRI-treated mice when compared to sham-
treated mice (P < 0.0001 for both) (Figures 5B,C, Table 2).
Similarly, the frequency (P < 0.001) and proportion of FCs (P <
0.001) was significantly greater in the colon from post-treatment
IRI mice than in sham-treated mice (Figures 5B,C, Table 2).
Mucosal Damage and Intestinal
Inflammation Following Irinotecan
Administration
Histological structure of the colons from the sham-treated
animals at days 3, 7, 14, and post-treatment appeared healthy
with a visible brush border as well as uniform crypts (total
histological score = 5) (Figures 6A–D,E). Severe mucosal
ulceration and crypt distension was observed in the colon from
the IRI-treated group at day 3 (total histological score = 17)
(Figures 6A′,E). Colon sections from IRI-treated mice at days
7 (total histological score = 12) (Figures 6B′,E) and 14 (total
histological score= 12) (Figures 6C′,E) displayed severemucosal
ulceration coupled with crypt hypoplasia and disorganization,
which were not observed in colonic preparations from sham-
treated mice. Colon sections from post-treatment IRI mice
displayed crypt hypoplasia and disorganization, but the epithelial
brush border was visible and appeared to be restored (total
histological score= 8) (Figures 6D′,E).
To investigate if acute and chronic IRI treatment causes
inflammation, immune cell infiltration in the colon was analyzed.
Immune cells in colonic cross sections were labeled with a
pan-leukocyte marker anti-CD45 antibody following 3, 7, 14
days and post IRI treatment compared to sham-treated mice
(Figures 7A–D′). Total numbers of CD45 positive cells were
counted within a 2 mm2 area. A significant increase in the
number of CD45 positive cells was found in the colon following
3 (sham: 45 ± 9; IRI: 109 ± 3, P < 0.0001), 7 (sham: 47 ± 3; IRI:
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FIGURE 5 | Effects of in vivo IRI treatment on the colonic motility. (A) Representative spatiotemporal maps generated from digital video recordings of colonic motility
from sham and IRI-treated mice. Each contraction can be seen as a reduction in the gut width (red/yellow), while relaxation as an increase in the gut width
(blue/green). Colonic migrating motor complexes (CMMCs) propagate >50% of the colon length, short contractions (SCs) propagate <50% of the colon length and
fragmented contractions (FCs) are interrupted by period(s) of relaxation during contraction. (B) Frequency of contractions including all types of contractile activity and
frequency of specific types of contractions in the colons from sham and IRI-treated mice. (C) The proportion of CMMCs, SCs and FCs to the total number of
contractions. Gray columns: sham-treated, black columns: IRI-treated. Data presented as mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001,
compared to day 14 sham, n = 5 mice/group.
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TABLE 2 | Parameters of different types of colonic contractions following repeated in vivo irinotecan or sham treatment.
Day 14 sham Day 14 IRI Post-treatment Sham Post-treatment IRI
Total Contractions (per 15min) 27.7 ± 1.8 41.1 ± 1.9** 25.9 ± 1.0 47.7 ± 3.1****
Frequency CMMCs (per 15min) 11.0 ± 0.9 1.6 ± 0.7**** 10.0 ± 0.4 3.8 ± 1.4***
Proportion CMMCs (%) 40.6 ± 2.5 4.6 ± 2.1**** 38.7 ± 2.4 11.5 ± 3.5****
Frequency SCs (per 15min) 10.2 ± 1.8 15.6 ± 1.8* 9.1 ± 0.7 17.2 ± 1.9**
Proportion SCs (%) 35.8 ± 3.6 38.2 ± 3.9 35.4 ± 3.5 32.1 ± 1.6
Frequency FCs (per 15 min) 6.0 ± 1.16 23.8 ± 2.5**** 6.6 ± 1.2 26.7 ± 3.1***
Proportion FCs (%) 23.7 ± 2.3 57.3 ± 4.4**** 25.4 ± 4.4 56.4 ± 4***
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, significantly different to Day 14 sham-treated mice, n = 5 per group/time point.
92± 5, P < 0.0001), and 14 days (sham: 42± 3; IRI: 98± 2, P<
0.0001) of IRI administration when compared to sham treatment.
This increase persisted in post-treatment IRI mice (92 ± 7, P <
0.0001) compared to sham (44± 1) group (Figure 7E).
Neuronal Loss and Changes in Cholinergic
Neurons and Fibers Following Repeated In
vivo Administration of Irinotecan
To investigate changes to the total number of myenteric neurons
wholemount preparations were labeled with a pan-neuronal
marker anti-PGP9.5 antibody (Figure 8). Repeated in vivo
administration of IRI induced myenteric neuronal loss when
compared to the sham-treated groups at days 7 (sham: 1,218 ±
17; IRI: 1,092± 2, P< 0.05) and 14 (sham: 1,262± 34; IRI: 1,072
± 23, P< 0.05) (Figure 9A). This neuronal loss persisted in mice
post IRI treatment (sham: 1,232± 32; IRI: 1,038± 52, P < 0.01).
No significant difference in numbers of myenteric neurons was
found at day 3 (sham: 1,222± 9; IRI: 1,171± 22) (Figure 9A).
To determine if IRI administration was associated with
changes in a specific subpopulation of myenteric neurons, the
average number and proportion of neurons immunoreactive
(IR) for ChAT specific to cholinergic neurons was analyzed in
both sham and IRI-treated mice (Figure 8). Repeated in vivo
administration of IRI induced a significant increase in the average
number of ChAT-IR neurons when compared to sham-treated
group at days 3 (sham: 293 ± 9; IRI: 372 ± 6, P < 0.0001), 7
(sham: 325± 3; IRI: 390± 5, P< 0.001), 14 (sham: 320± 15; IRI:
390 ± 3, P < 0.0001) and post-treatment (sham: 306 ± 15; IRI:
401 ± 10, P < 0.0001) (Figure 9B). The proportion of ChAT-IR
neurons significantly increased at all time points (Figure 9C).
The define whether increase in ChAT expression in
neuronal cell bodies was due to the increased synthesis or
decreased transport and release of acetylcholine, cholinergic
fibers were labeled within myenteric ganglia in wholemount
preparations of the colon using anti-VAChT antibody at
day 14 and post IRI treatment (Figures 10A–B’). Repeated
in vivo administration of IRI induced a significant increase
in the density of VAChT-IR fibers in the myenteric
plexus at day 14 (sham: 4.0 ± 0.2; IRI: 10.3 ± 0.3, P <
0.0001) and post-treatment compared to the sham-treated
group (sham: 4.2 ± 0.2; IRI: 12.6 ± 0.5, P < 0.0001)
(Figure 10C).
DISCUSSION
This study is the first to investigate IRI-induced enteric
neuropathy, colonic motility, and gastrointestinal function in
mice. The results show that changes in intestinal transit
and increased motor activity are associated with symptoms
of diarrhea evidenced by increased pellet length and fecal
water content. Although repeated administration of IRI causes
severe mucosal damage to the murine colon throughout the
experimental period, post-treatment colons showed signs of
epithelial regeneration. However, increased leukocyte infiltration
was found both during the treatment period and after 7 days
post-treatment. Increased intestinal transit time taken together
with very high fecal water content at day 3 of IRI administration
indicate that at this time point diarrhea had significant secretory
component, whereas unchanged intestinal transit time, delayed
intestinal emptying and long pellets with increased water content
observed at later time points as well as significant changes
in colonic motility at day 14 were associated with delayed
onset/chronic diarrhea. This study is the first to demonstrate a
distinct difference in both the pathophysiology and functional
consequences of acute and delayed onset/chronic IRI-induced
diarrhea. Acute diarrhea associates with significant increases in
the number of ChAT-immunoreactive neurons and the density of
cholinergic nerve fibers observed at Day 3 of IRI administration
leading to increased secretion, whereas symptoms of chronic
diarrhea at days 7, 14, and post-treatment may result from the
damage and loss of enteric neurons observed at these time points
leading to impaired motility. Taken together our results implicate
intestinal inflammation, neuronal loss and phenotypic changes
with increased numbers of cholinergic neurons and fibers in the
pathogenesis of irinotecan-induced gastrointestinal dysfunction
underlying diarrhea.
Gastrointestinal mucositis is a frequent and debilitating
complication resulting from the systemic effects of cytotoxic
chemotherapy and the local effects of radiotherapy (Avritscher
et al., 2004). Inflammation, epithelial degradation, and intestinal
ulceration, manifesting as mucositis, are well-established
consequences of IRI administration (Duncan and Grant,
2003; Sonis et al., 2004; Stringer et al., 2009a,b). Although the
incidence and severity of mucositis varies greatly according to
patient characteristics and treatment regimens, the prevalence
of IRI-induced gastrointestinal mucotoxicity in the form of
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FIGURE 6 | Gross morphological change in the colon following repeated in vivo IRI administration. H&E staining in the colon from sham-treated and IRI-treated mice
at 3 (A,A′), 7 (B,B′), 14 (C,C′) days, and 7 days post-treatment (D,D′). Scale bar = 100 µm. Histological scoring of morphological changes in the colon (E). Data
presented as mean ± S.E.M. ****P < 0.0001, n = 5 mice/group.
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FIGURE 7 | CD45+ leukocytes in the colon. Cross sections of the colon labeled with a leukocytes marker anti-CD45+ antibody (green) from sham-treated and
IRI-treated mice at 3 (A,A′), 7 (B,B′), 14 (C,C′) days, and 7 days post-treatment (D,D′). Scale bar = 100 µm. Number of CD45+ cells was counted within 2mm2 of
the mucosa in the colon sections from sham and IRI-treated mice at 3, 7, and 14 days, and 7 days post-treatment (E). Gray columns: sham-treated, black columns:
IRI-treated mice. Data represented as mean ± S.E.M. ****P < 0.0001, n = 5 mice/group.
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FIGURE 8 | Wholemount preparations of myenteric plexus. Myenteric neurons were labeled using a pan-neuronal marker anti-PGP9.5 antibody (magenta) and
cholinergic neurons were labeled using anti-ChAT antibody (green) in the wholemount preparations of the colon from sham-treated and IRI-treated mice at 3 (A,A′), 7
(B,B′), 14 (C,C′) days and 7 days post-treatment (D,D′). Scale bar = 50 µm.
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FIGURE 9 | Effect of repeated in vivo IRI administration on the total number of
neurons and average number and proportion of ChAT-IR myenteric neurons.
(A) Average number of PGP9.5-IR neurons in the colon was counted per 2mm2
(Continued)
FIGURE 9 | Continued
at 3, 7, and 14 days, and 7 days post-treatment in both sham and IRI-treated
mice. (B) Average number of ChAT-IR neurons in the colon was counted per
2mm2 at 3, 7, and 14 days and 7 days post-treatment in both sham and
IRI-treated mice. (C) Proportion of ChAT-IR neurons calculated to the total
number of PGP9.5-IR myenteric neurons in the colon per 2mm2 at 3, 7, and
14 days and 7 days post-treatment in both sham and IRI-treated mice. Gray
columns: sham-treated, black columns: IRI-treated mice. Data presented as
mean ± S.E.M. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n = 5
mice/group.
secretory diarrhea has been reported to be as high as 87%
(Rougier et al., 1998; Avritscher et al., 2004). Our results show
severe mucosal ulceration, crypt hypoplasia and disorganization
in the colon following both short and long-term IRI treatment.
A significant increase in CD45+ leukocytes in colonic mucosa
observed following 3 days of IRI administration persisted
throughout the course of treatment as well as post-treatment
in our study. This is in line with previous reports for the
rat jejunum and colon following IRI treatment, where villus
blunting, epithelial atrophy and crypt ablation were reported
(Logan et al., 2008). However, in our study, mucosal regeneration
is evident in post-treatment mice in which colonic crypts are
still disorganized, but the epithelial brush border has recovered.
Acute intestinal toxicity associated with anti-cancer treatment
is believed to result from crypt cell death, which triggers
mucosal inflammation and breakdown of the intestinal mucosal
barrier, however controversy exists regarding whether this is a
direct result of cytotoxicity or is mediated through a series of
intermediate events (Sonis et al., 2004).
The basic pathophysiology of mucositis may be broken into
5 sequential phases (i) initiation; (ii) up-regulation and message
generation; (iii) signaling and amplification; (iv) ulceration and
inflammation; and (v) healing (Sonis et al., 2004; Lee et al.,
2014). In the healing phase, proliferation and differentiation of
the gastrointestinal epithelium returns approximately 2 weeks
post-chemotherapy (Sonis et al., 2004; Lee et al., 2014). Mucosal
regeneration has been confirmed in human studies showing that
early histological changes in the gastrointestinal tract following
chemotherapeutic administration are resolved within days of
treatment cessation, with no abnormal endoscopic findings in
patients as early as 16 days post-chemotherapeutic treatment
(Keefe et al., 2000). However, although histological damage has
resolved, long-term diarrhea following chemotherapy treatment
persists up to 10 years post-treatment (Schneider et al., 2007;
Denlinger and Barsevick, 2009; Numico et al., 2015). Similar
results have been found in pelvic radiation therapy, during which
intestinal permeability and mucosal injury peak mid-treatment
then gradually improve, while nausea, diarrhea and abdominal
pain persist throughout the course of treatment (Carratù et al.,
1998; Hovdenak et al., 2000). It has been suggested that crypt cell
death in radiation syndrome is triggered indirectly by apoptotic
endothelial lesions (Paris et al., 2001), highlighting that intestinal
dysfunction at least in part, may be a consequence of an indirect
cascade of events mediated by non-epithelial tissues (Sonis et al.,
2004).
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FIGURE 10 | Effect of repeated in vivo IRI administration on the density of VAChT-IR cholinergic fibers in the myenteric plexus. Wholemount preparations of VAChT-IR
(green) fibers in the myenteric ganglia of the colon from sham and IRI-treated mice at 14 days (A,A′) and 7 days post-treatment (B,B′) Scale bar = 25 µm. (C) Density
of VAChT-IR fibers in the myenteric plexus was analyzed at 14 days and post-treatment in both sham and IRI-treated mice. Gray columns: sham-treated, black
columns: IRI-treated mice. Data presented as mean ± S.E.M. **P < 0.01, ****P < 0.0001, n = 5 mice/group/time point.
Although the underlying mechanisms of delayed onset and
long-term diarrhea remain unclear, early mucosal damage,
and acute intestinal inflammation can lead to death and
damage of enteric neurons resulting in long-term gastrointestinal
dysfunction (Boyer et al., 2005; Linden et al., 2005; Nurgali
et al., 2007, 2011). Our study is the first demonstrating that
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repeated administration of IRI results in myenteric neuronal loss
of up to 16% from day 7 to post-treatment. Given its cell cycle
specificity, IRI is believed to have relatively no toxic effect on
differentiated post-mitotic cells such as neurons. However, the
IRI analog camptothecin administered at concentrations that
inhibit Top-I has been found to induce apoptosis in cortical
neurons (Morris and Geller, 1996). Despite the significant loss
of myenteric neurons at Days 7 and 14 which persisted 7 days
post-treatment, both the absolute number and the proportion of
ChAT-IR neurons in the myenteric plexus were increased as early
as 3 days following IRI treatment, with increases of up to 17%
persisting throughout all experimental time-points and in post-
treatment mice. The increased proportion of ChAT-IR neurons
might be due to either a preferential loss of other neuronal
sub-types with preferential sparing of ChAT-IR neurons or to
phenotypic changes in myenteric neurons. However, the increase
in the absolute number of ChAT-IR neurons alongside neuronal
loss can only be due to phenotypic changes in myenteric neurons
leading to increased ChAT expression as opposed to preferential
loss of other neurons. Furthermore, it has been shown previously
that IRI binds to the active site of acetylcholinesterase resulting in
functional inhibition of the enzyme and increased persistence of
extracellular acetylcholine (Dodds and Rivory, 1999; Harel et al.,
2005).
To determine if the increase in ChAT-IR neurons was
accompanied by increased cholinergic innervation of the muscle,
we quantified the density of cholinergic fibers containing VAChT,
a transporter responsible for transferring acetylcholine into
vesicles. IRI-treated mice had significantly higher densities of
VAChT-IR fibers at day 14 and post-treatment. The increase
in VAChT-IR is consistent with the possibility that IRI induces
increased numbers of cholinergic motor neurons; however, the
sprouting or new branches of pre-existing cholinergic motor
neurons as well as increased density of extrinsic VAChT-IR fibers
cannot be excluded. Moreover, whether increased synthesis of
acetylcholine occurs only in cholinergic neurons making them
easier to identify or whether non-cholinergic neurons start
expressing ChAT needs to be further determined. In addition,
the increase in the proportion of ChAT neurons may, in part, be
due to a selective loss of other neuronal subtypes. Further analysis
of other neuronal subtypes including nNOS-IR inhibitory motor
neurons is warranted.
Taken together, these data suggest that IRI induces increase
in enteric neuronal acetylcholine synthesis and release as
well as reduced degradation leading to an excessive amount
of acetylcholine, known as cholinergic syndrome, affecting
physiological functions of the gut. Cholinergic neurons are a
vital component of the excitatory motor innervation of the
colon (Furness, 2012). Acetylcholine is a major excitatory
neurotransmitter responsible for the contractions of circular
and smooth muscle (Furness, 2012) and mucosal secretion
(Cooke, 2000). Acute diarrhea experienced within the first 24 h
of IRI treatment has been attributed to cholinergic syndrome
in colorectal cancer patients (Hecht, 1998). Delayed onset and
long-term diarrhea are, however, believed to be multifaceted
(Bleiberg and Cvitkovic, 1996; Saliba et al., 1998). Our results
demonstrated increased intestinal transit accompanied by faster
pellet formation at day 3 of IRI treatment. Although intestinal
transit returned to sham levels at later time points, the increased
motor activity in the colon associated with symptoms of diarrhea
(increased pellet length and fecal water content) persisted at
both day 14 and post-treatment. It has previously been shown
that colonic propulsion speed correlates positively with pellet
length (Costa et al., 2015). Our data indicate increased colonic
propulsive activity and presence of diarrhea in IRI-treated mice.
The total number of contractions following IRI administration
was significantly higher due to increases in both the number
and proportion of short and fragmented contractions. Short and
segmenting contractions play a central role in the formation
of productive motor patterns in the healthy intestine (Gwynne
et al., 2004). Short distance contractions result in segmentation of
the colon, which is essential for mixing and absorption of colonic
contents (Huizinga and Chen, 2014). Chemotherapy-induced
neuronal loss in the myenteric plexus has been previously shown
in mice and rats following administration of various agents.
Downstream effects on colonic motility and gastrointestinal
transit following administration with platinum compounds
cisplatin and oxaliplatin (Vera et al., 2011; Wafai et al., 2013; Pini
et al., 2016) have been associated with increased proportions of
nNOS neurons and oxidative stress in enteric neurons, whilst
administration with fluoropyrimidine 5-fluorouracil has been
correlated with intestinal inflammation (McQuade R. et al., 2016;
McQuade R. M. et al., 2016). These findings highlight that enteric
neuropathy may be a critical component in the development
of long-term chemotherapy-induced gastrointestinal
dysfunction.
In conclusion, this study demonstrates that IRI treatment
induces mucosal damage and inflammation which may
contribute to neuronal loss and phenotypic changes in
the myenteric plexus. Increased expression of ChAT-IR
neurons and VAChT-IR nerve fibers in the myenteric
plexus may underlie alterations in colonic motor activity
and gastrointestinal transit following IRI treatment resulting
in chronic gastrointestinal dysfunction. This study is the
first to show that neuropathic changes in the gut may be
key players in the manifestation of delayed-onset and long-
term chronic diarrhea that persists after the cessation of IRI
treatment.
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